Precision BioSciences Inc. (DTIL)
DTIL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1357874/000162828026017019/0001628280-26-017019-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | DTIL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001357874 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $34.3M |
| Net income | -$45.7M |
| Operating income | -$52.1M |
| Net margin | -133.4% |
| Operating margin | -152.2% |
| Revenue growth | -50.1% |
| Cash | $110.8M |
| Total assets | $154.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 8.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $81.7M cash; operating cash flow -$12.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 27,935,719 (2026-10-29); 13,256,751 a year earlier; 118,935,191 three years earlier. 3y figure adjusted for split (1-for-30 overall). | Cover page 2026-10-29 |
| Reverse splits, 3 years | 1; latest 1-for-30 on 2024-02-14 | Source 2024-02-14 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-11-06 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Raleigh, North Carolina, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $63K, sold $447K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$7.6M | -$15.1M | $81.7M | $22.4M | $45.0M | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $0 | -$32.7M | -$13.4M | $86.1M | $22.4M | $45.1M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $10.8M | -$18.4M | -$11.9M | $99.4M | $22.4M | $45.1M | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $34.2M | $20.1M | -$11.3M | $110.8M | $22.4M | $34.3M | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | $13K | -$21.8M | -$15.3M | $44.9M | $22.4M | $698K | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | $18K | -$23.5M | -$20.3M | $62.2M | $22.4M | $1.3M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $29K | -$20.6M | -$19.1M | $77.2M | $22.3M | $51.1M | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $638K | -$17.7M | -$18.7M | $85.9M | $22.3M | $68.7M | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-11-06 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-08 |
Source: SEC EDGAR submissions feed, 611 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -28.6% |
| 1 month | +24.0% |
| 3 months | +3.6% |
| Year to date | +81.9% |
| 1 year | +29.3% |
| From 52-week high | -28.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ALLO | Allogene Therapeutics Inc. | $0.8070 | -3.78% | $279.6M |
| AGEN | Agenus Inc. | $6.29 | -6.54% | $284.6M |
| SABS | SAB Biotherapeutics Inc. | $3.00 | +1.35% | $270.3M |
| EDIT | Editas Medicine Inc. | $1.87 | -13.82% | $288.6M |
| XFOR | X4 Pharmaceuticals Inc. | $2.83 | -9.29% | $289.0M |
| LXEO | Lexeo Therapeutics Inc. | $3.23 | +12.54% | $265.0M |
| SCTX | Scribe Therapeutics Inc. | $15.37 | -6.05% | $291.1M |
| EIKN | Eikon Therapeutics Inc. | $5.38 | -9.95% | $291.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier